Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Akebia Therapeutics Inc (NASDAQ:AKBA) announced topline results from the FO2CUS study evaluating the efficacy and safety of vadadustat in hemodialysis patients converted from a long-acting erythropoiesis-stimulating agent (ESA) to three times weekly oral vadadustat dosing for the maintenance treatment of anemia.
- The data demonstrated that vadadustat met the primary and secondary efficacy endpoints and was non-inferior to an ESA with a similar safety profile to the current standard of care.
- FO2CUS was an open-label, active-controlled, sponsor-blinded study that evaluated 456 hemodialysis patients.
- In the FO2CUS study, each vadadustat dosing regimen (600mg, 900mg) and the combined vadadustat-treated group achieved the primary efficacy endpoint of the mean change in Hb between baseline and the primary evaluation period compared to Mircera in adult patients on hemodialysis, demonstrating non-inferiority to Mircera based on a non-inferiority margin of -0.75 g/dL.
- Similarly, each dosing regimen of vadadustat and the combined vadadustat-treated group achieved the secondary efficacy endpoint of the mean change in Hb between baseline and the secondary evaluation period.
- Akebia expects to present full study results at an upcoming medical conference or in a peer-reviewed journal this year.
- Price Action: AKBA shares are up 0.92% at $0.5656 on the last check Monday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!